Urinary podocalyxin as a novel prognostic biomarker for early diagnosis of diabetic kidney disease and its outcome with telmisartan – a prospective observational study

The kidneys act as the body's intricate filtration system, sifting waste from the blood while holding onto essential nutrients. In people with type 2 diabetes, high blood sugar can slowly damage the delicate structures inside these filters. One of the first signs of this damage often appears as albumin, a protein that leaks into the urine. Doctors have long relied on measuring this protein, known as albuminuria, to detect early kidney trouble. However, this traditional method has a blind spot. It measures the result of damage after the filtration barrier has already been compromised, much like noticing a leak in a roof only after water has pooled on the floor. Before the leak becomes obvious, the tiny cells responsible for keeping the roof intact—the podocytes—may already be injured and shedding their protective coating.

Researchers have been searching for a way to spot this injury much earlier, right when the cells begin to struggle. A specific protein called podocalyxin sits on the surface of these podocytes, acting as a shield that helps them maintain their shape and keep the filtration barrier tight. When these cells are hurt, they shed this protein into the urine. Detecting urinary podocalyxin offers a potential window into the structural health of the kidney before the more obvious signs of disease appear. Understanding whether this marker can reliably signal early trouble, and whether it responds to treatment, could change how doctors monitor and manage kidney disease in people with diabetes.

A team of researchers at SRM Institute of Science and Technology in India set out to test this idea in a prospective observational study involving 82 patients with type 2 diabetes. The goal was to see if measuring urinary podocalyxin could serve as an early warning system and to observe how these levels changed when patients were treated with telmisartan, a medication known to protect the kidneys. The study followed these patients over six months, taking detailed measurements at the start and again after treatment. The researchers looked at standard markers like blood sugar and creatinine, but their primary focus was on the relationship between the traditional protein leak and the new podocyte marker.

At the beginning of the study, the team found that urinary podocalyxin was already elevated or suspicious in the vast majority of patients, even in those whose traditional albumin levels were still within a safer range. This suggests that the structural damage to the kidney's filtering cells was happening before the more common signs of disease became apparent. There was a clear link between the two markers: patients with higher levels of the traditional protein leak also tended to have higher levels of the podocyte protein. This connection indicated that the two measurements were reflecting the same underlying injury, but the podocyte marker was sensitive enough to catch the problem earlier.

When the patients began taking telmisartan, the results showed a significant improvement in their kidney health markers. After six months of treatment, the average level of the traditional protein leak dropped substantially, falling from a baseline of 101.43 mg/g to 63.54 mg/g. More importantly, the levels of urinary podocalyxin also decreased markedly, dropping from an average of 1.67 ng/mL to 0.74 ng/mL. This parallel reduction suggests that the medication was not just reducing the symptom of protein leakage but was also helping to repair or stabilize the injured cells themselves. While the patients' blood sugar levels and serum creatinine, a standard measure of kidney function, did not change significantly, the specific markers of cell injury showed a clear positive response to the therapy.

The study also looked at whether age or gender influenced how well the treatment worked. The data showed that the reduction in both protein markers was consistent across different age groups and between men and women. Whether a patient was in their forties or their seventies, the medication appeared to have a similar effect on the kidney cells. This uniformity suggests that the treatment's ability to protect the podocytes is reliable regardless of the patient's demographic profile. The researchers noted that while the sample size was relatively small and the study was conducted at a single center, the findings were statistically significant and pointed toward a clear trend.

These findings support the idea that urinary podocalyxin is a sensitive tool for spotting early kidney damage in people with diabetes. It appears to detect injury at a stage where traditional tests might still look normal, offering a chance for earlier intervention. Furthermore, the fact that these levels dropped significantly after treatment indicates that the marker can be used to monitor how well a therapy is working to protect the kidney's delicate structure. While larger studies are needed to confirm these results and establish standard guidelines, this research highlights a promising shift from simply measuring the consequences of kidney damage to observing the health of the cells that prevent it.